Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2022 · 10-Q
Revenue$77.00K$77.00K−86.8% vs Q1 2021 Net Income-$1.79M-$1.79MN/M vs Q1 2021 EPS Diluted-$0.04-$0.04N/M vs Q1 2021 Gross Profit$26,000−43.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$1,851,000N/M Free Cash Flowderived-$1,944,000N/M Margins · derivedGross margin33.8%+25.9 pt vs Q1 2021
Operating margin-2849.4%−2518.7 pt vs Q1 2021
Net margin-2322.1%−1999.8 pt vs Q1 2021
ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end